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Abstract: Diabetes mellitus is increasing worldwide. Type 1 diabetes can be treated success-
fully by islet allotransplantation, the results of which are steadily improving. However, the 
number of islets that can be obtained from deceased human donors will never be sufficient to 
cure more than a very small percentage of patients who might benefit from transplantation. 
Although there are some differences in glucose metabolism between pigs and humans, the use 
of pigs could provide an unlimited supply of islets, and the insulin produced would undoubtedly 
control glucose levels. Transplantation of islets into the portal vein results in islets residing in the 
liver; however, an early inflammatory response and rejection remain problematic, even when the 
recipient is receiving immunosuppressive therapy. In the long term, immunosuppressive drugs 
may exhibit toxicities to patients and specifically harm the islet cells. In contrast, encapsula-
tion techniques provide islets with a physical barrier that prevents antibodies binding to the 
islet graft while still allowing insulin to be released into the recipient’s circulation; in theory, 
patients receiving encapsulated grafts might not require exogenous immunosuppressive therapy. 
Nonhuman primates with encapsulated pig islet transplants have remained insulin-independent 
for several weeks, but long-term efficacy remains uncertain. Furthermore, techniques are now 
available to knock out genes from the pig and/or insert human genes, thus rendering the antigenic 
structure of pigs closer to that of humans, and providing protection from the human immune 
response. Islet transplantation from genetically engineered pigs has been followed by insulin 
independence in a small number of nonhuman primates for greater than 1 year. Neonatal islets 
have some advantages over adult islets in that they are easier to isolate and culture, and have the 
ability to proliferate during the first few months after transplantation. In 2009, the International 
Xenotransplantation Association set up a group to encourage and advise on clinical trials of pig 
islet xenotransplantation; this group’s guidelines are discussed. Clinical trials of encapsulated 
pig islets are already under way.
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The problem of type 1 diabetes
Diabetes is increasing in frequency worldwide, not only in the Western world, but 
in many of the most populous countries of Asia, as Western culture, including diet, 
encroaches upon traditional ways of life (Table 1). Furthermore, diabetes is already 
epidemic, with an increasing health burden that in some countries absorbs .10% of 
their annual expenditure for health care.1
Diabetes has traditionally been subdivided into type 1 (T1D; autoimmune) and 
type 2 (T2D; with insulin resistance and metabolic syndrome); however, this subdivision 
is an oversimplification, with the current notion that several different mechanisms can 
lead to the onset of diabetes.2 It is relevant to note that as recently as three decades ago, 
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Table 1 Reported incidence of diabetes in selected countries 
worldwide
Region Estimated overall  
prevalence of  
T1D + T2D in  
millions (% of adult  
population)
Estimated 
new cases of 
T1D in 2011 
(per 100,000 
population)
europe 52.6 (8.1%) 17,800 (1.9)
Southeast Asia  
(includes india)
71.4 (8.3%) 18,000 (1.2)
North America  
and Caribbean
37.7 (7.8%) 14,600 (3.0) 
(15,600 in US)
South and  
Central America
25.1 (8.7%) 5,500 (1.1)
Middle east and  
North Africa
32.8 (9.1%) 10,800 (1.7)
Africa 14.7 (3.8%) 5,900 (0.7)
Western Pacific (includes  
People’s Republic of China)
131.9 (8.5%) 5,000 (0.2)
Note: Data from.54,55
Abbreviations: T1D, type 1 diabetes; T2D, type 2 diabetes.
all diabetic children and adolescents were assumed to have T1D, 
whereas more recently the incidence of T2D among pubertal 
and postpubertal adolescents has risen  dramatically.3 Despite the 
different etiology, the consequences of both types of diabetes 
are similar and account for increased risk for cardiovascular 
disease, neuropathy, blindness, and kidney failure. According 
to the current statistics, diabetes is the fourth-leading cause of 
death worldwide.4 New glucose-lowering treatments, especially 
glucagon-like peptide 1-receptor agonists and sodium glucose 
cotransporter-2 inhibitors, offer advantages over traditional 
antidiabetic drugs used to regulate T2D by promoting weight 
loss while improving glucose control.5 However, exogenous 
insulin injections are the only effective treatment for T1D unless 
a transplant (pancreas or pancreatic islets) is carried out.
Pancreas transplantation is an effective approach to treat 
T1D. According to the American Diabetes Association, it 
should be considered an acceptable therapeutic alternative to 
continued insulin therapy in diabetic patients with imminent 
or established end-stage renal disease, who have had or plan 
to have a kidney transplant. In the absence of indications 
for kidney transplantation, pancreas transplantation alone 
should be considered in patients who have severe metabolic 
complications and failure of insulin-based management.6 At 
present, only adult patients meet the requirements for pan-
creas transplantation, due to the invasiveness of the surgery 
required and the relatively high incidence of complications 
associated with the procedure. It is not recommended for 
pediatric and adolescent patients, those individuals who 
would most benefit from effective β-cell replacement.
In contrast, transplantation of pancreatic islets holds signifi-
cant potential advantages over whole-pancreas transplantation. 
In this procedure, islets are extracted from the pancreas of 
deceased donors by means of a process based on digestion 
with exogenous enzymes (collagenases and neutral proteases). 
Islets are then rescued from the exocrine tissue via a process of 
density-gradient separation. Although mechanical and chemi-
cal stresses necessary to the isolation process may potentially 
damage some of the islets, this risk can be minimized by the 
careful application of the techniques involved. Islet cells 
can survive up to several days in culture, maintaining their 
ability to secrete insulin in vitro, and following transplanta-
tion, in vivo. Isolated islets are typically transplanted via 
intraportal injection. Islet infusion is usually carried out by a 
minimally invasive procedure, such as percutaneous transhe-
patic portal catheterization guided by ultrasound.
The risks associated with islet transplantation are sub-
stantially lower than those of whole-pancreas transplantation, 
making it more suitable, especially for adolescents, who would 
potentially receive the benefits over many years. More than 
one infusion – corresponding to an islet mass obtained from at 
least two cadaveric pancreas donors – is typically required to 
achieve insulin independence. The need for a greater number 
of donor organs for islet transplantation, in comparison to 
whole-pancreas transplantation, is in part counterbalanced 
by the fact that islets can be isolated from marginal donors 
not suitable for whole-pancreas transplantation (eg, because 
of vascular abnormalities or fatty organs).
Both pancreas and islet transplantation require lifelong 
immunosuppressive therapy to prevent rejection. Islet 
transplantation has been shown to be an effective treatment 
for T1D. Increased experience with the procedure, and the 
techniques involved with it, have produced steadily improving 
results. Insulin independence can now be maintained for at 
least 3 years in .50% of patients. The single major limit-
ing factor of this technique, however, is the finite number 
of acceptable human cadaveric pancreases available. The 
number of islets that can be obtained from deceased human 
donors will never be sufficient to treat more than a very 
small percentage of patients with T1D, especially considering 
the need for more than one pancreas to produce sufficient 
islets for one recipient. Another source of acceptable islets 
is greatly needed.
Pigs as a source of islet cells  
for transplantation
Tissues from pigs have been routinely and safely used 
for medical purposes for decades. Although there are 
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some  differences in glucose metabolism between pigs and 
humans,7 pigs could provide an unlimited supply of islets 
for transplantation into patients with T1D, and the insulin 
produced would likely control blood glucose levels. Pig 
insulin (which differs from human insulin by only one 
amino acid) was used in the treatment of patients with T1D 
for many decades until recombinant human insulin was 
synthesized.8
T1D occurs when the autologous immune cells target 
antigens expressed in the insulin-producing cells of the 
pancreas. As a result of this selective destruction of islet 
β-cells by autoreactive T lymphocytes, the ability to produce 
insulin sufficient to maintain normal levels of glucose in the 
body is lost, resulting in hyperglycemia. Recurrence of auto-
immunity has been reported in both recipients of allogeneic 
pancreas and islet transplantation, where it contributes to 
β-cell graft destruction.9,10 The immunosuppressive therapy 
administered to organ and cell-transplant recipients to prevent 
rejection establishes hyporesponsiveness toward the graft, but 
it also modulates autoreactive T cells as well, making recur-
rent autoimmunity in transplant recipients somewhat less 
destructive, although not completely eliminated. However, 
drugs that suppress the immune system are associated with 
increased risk of infections and malignancies, and some 
immunosuppressive agents are known to have islet β-cell 
toxicity.
The question whether xenogeneic islet transplantation 
might avoid recurrent autoimmunity in patients with T1D 
is being studied, but has yet to produce a definitive answer. 
Promising lines of inquiry carried out in models of pig islet 
transplantation into nonobese diabetic mice (“NOD” mice 
that spontaneously develop autoimmune diabetes similar 
to T1D in humans) show that adult pig islets are partially 
resistant to recurrent autoimmunity11 and pig fetal islets are 
likely even more resistant.12 The results of islet transplanta-
tion in the pig-to-mouse model, if confirmed, offer several 
very relevant advantages of xenoislet transplantation over 
allogeneic islet transplantation.
Another potentially important feature of porcine islet 
β-cells is that unlike human β-cells, they do not overproduce 
amyloids. Islet amyloid polypeptide (amylin) is secreted from 
pancreatic islet β-cells and converted to amyloid deposits. 
Amylin-fibril formation in the pancreas may cause islet-cell 
dysfunction and death.13 Porcine amylin differs from the 
human sequence at ten positions, and includes substitutions 
predicted to reduce its amyloidogenicity.14 Lack of amyloid 
deposits in the islet β-cells after pig islet transplantation in 
diabetic monkeys has also been confirmed.15
The first documented clinical trial of pig-to-human 
islet xenotransplantation (more exactly fetal islet-like cell 
clusters) took place as early as 1994.16 Porcine pancreatic 
cells were injected intraportally or placed under the capsule 
of a kidney allograft. Some patients excreted small amounts 
of porcine C peptide in the urine for more than 6 months, and 
biopsy specimens showed morphologically intact epithelial 
cells stained positively for both insulin and glucagon. None 
of the patients, however, demonstrated an improvement in 
metabolic control.16
Experimental transplantation has contributed in the last 
two decades to shed light on the critical mechanisms occur-
ring after islet xenotransplantation. We now know that when 
pig islets are transplanted into the portal vein of diabetic 
nonhuman primates (NHPs), there is an immediate and 
significant loss of islets from a complex interplay between 
several mechanisms known as the instant blood-mediated 
inflammatory reaction (IBMIR),17 and rejection of the islets 
takes place fairly rapidly.18 Both of these phenomena (IBMIR 
and rejection) are related to differences in the expression of 
antigens between the pig and NHPs, and would necessarily 
be the same between the pig and humans.
In vitro exposure of pig islets to human blood triggers 
coagulation, islet-membrane leakage, antibody deposition, 
soluble complement activation, including the membrane 
attack complex, and mitochondrial dysfunction.19,20 To some 
extent, some of these events occur also in autologous and 
allogeneic islet/blood combinations, but islet damage is worse 
in the xenogeneic setting.
Genetically engineered pigs
The ability to develop genetically engineered pigs has brought 
the prospect of successful pig islet xenotransplantation much 
closer to reality. Techniques are now available to knock out 
genes from the pig and/or insert human genes, thus rendering 
the pig closer in its antigenic structure to humans and provid-
ing protection from the human immune response. Humans 
and Old World monkeys have natural preformed antibodies 
(present in serum in the absence of an apparent specific 
antigen contact) against pig antigens,21,22 particularly against 
galactose-α1,3-galactose (Gal) that is expressed on many 
pig cells, including islets.23 When pig tissue is transplanted 
into humans or Old World monkeys, preformed natural 
antibodies bind to pig antigens and initiate complement 
activation, resulting in destruction of the graft vasculature 
with subsequent interstitial hemorrhage edema and graft 
failure. The pathophysiological mechanism is very similar to 
that seen when an allograft is transplanted across the ABO 
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blood-group barrier.24 For pig islet xenotransplantation to 
become fully successful, steps had to be taken to overcome 
this immune response in humans. After identifying the gene 
for α1,3-galactosyltransferase, which is the enzyme that 
synthesizes Gal,25,26 it was possible to knock out the gene by 
homologous recombination27 using somatic cell nuclear trans-
fer technology. The resulting α1,3-galactosyltransferase gene-
knockout (GTKO) pigs were first available for experimental 
studies in 2003.28 The transplantation of organs from GTKO 
pigs into NHPs resulted in a reduced incidence of hyper-
acute rejection.29,30 However, this was to a lesser extent than 
expected, suggesting that additional xenoantigens may exert 
a role in immunological incompatibility between species.
In addition, genes for human complement-regulatory 
proteins (eg, CD46, CD55) have been inserted into pig cells31 
in order to protect them from human complement-mediated 
injury. Furthermore, pigs that express one or more human 
thromboregulatory gene (eg, thrombomodulin, TFPI) and/or 
anti-inflammatory gene (eg, CD39) are being developed, with 
the aim of reducing thrombotic microangiopathy in the graft 
and/or systemic consumptive coagulopathy in the recipient 
(Wijkstrom et al, unpublished data, 2014).32–34
These measures have greatly reduced the innate immune 
response of human antibodies towards pig antigens, and the 
adaptive T-cell-dependent response can be largely controlled 
by the newer immunosuppressive agents that have become 
available. There is every prospect, therefore, that pig islets 
can be protected sufficiently to enable them to render the 
patient insulin-independent for a prolonged period of time 
(years, rather than weeks or months).
Pig islet transplantation  
in nonhuman primates
A number of groups have explored pig islet transplantation 
in NHPs rendered diabetic by streptozotocin. Within the 
last several years, the transplantation of neonatal or adult 
pig islets, or even embryonic pancreatic tissue, has been 
reported to restore normoglycemia for a period .6 months 
in the absence of exogenous insulin administration. Glycemic 
control was successfully achieved, however, at the cost of 
higher islet masses infused than those required in human 
allogeneic transplantation settings.35–37 Furthermore, one 
group has achieved this success using encapsulated adult 
pig islets in the absence of exogenous immunosuppressive 
therapy.38
Encapsulation techniques are aimed at providing a physical 
barrier that prevents antibody binding to the graft but enables 
insulin to be released from the graft into the recipient circulation.39 
In theory, immunosuppressive therapy should not be required 
to maintain graft function and survival. However, at the pres-
ent time, these techniques have only extended islet function 
for approximately 6 months. It is not yet certain whether loss 
of islet function is related to immune destruction of the graft 
or to lack of sufficient nutrients reaching the islets to maintain 
viability, because of pericapsular fibrosis.
In contrast, after the transplantation of free (nonencapsu-
lated) islets, eg, into the portal vein where they reside in the 
liver, IBMIR and rejection remain problematic even when the 
recipient is receiving immunosuppressive therapy. Efforts are 
being made to further genetic engineering pigs so that their 
islets are protected from IBMIR and rejection,39 and some 
progress is being made. For example, our own group has 
reported the survival of pig islets and control of diabetes in 
immunosuppressed diabetic NHPs for .1 year without the 
need for any insulin therapy (Figure 1).37,40
Neonatal islets have some advantages over adult islets, 
in that they are easier to isolate and culture and have the 
ability to proliferate during the first few months after 
transplantation.41,42 However, they express higher levels of 
Gal than adult pig islets, and therefore GTKO pigs are likely 
to prove essential in overcoming this hurdle. Islets from adult 
pigs are particularly difficult to isolate satisfactorily, as the 
islets have more fragile capsules than human islets and are 
more susceptible to damage by the isolation process. They 
are consequently more easily destroyed by the IBMIR than 
human islets.19 Neonatal islets may therefore prove preferable 
as a source for clinical transplantation.
Furthermore, as a practical consideration, the pigs used as 
sources of islets may be required to be housed in a strict bios-
ecure environment to prevent microorganisms from infecting 
the pig and possibly being transferred with the islets to the 
human recipient. It will be more efficient logistically, and 
more cost-effective, if the pancreases can be obtained from 
pigs during the first postnatal month, instead of after housing 
for a year or more until they have reached adult status.
Metabolic aspects of islet 
xenotransplantation
Besides immunological incompatibilities between humans 
and animals, metabolic aspects deserve consideration. 
Glucose homeostasis is the result of a complex biochemical 
regulation involving different internal systems. Insulin and 
glucagon are key hormones to maintain physiologic equilib-
rium, but multiple species-specific factors contribute to main-
tain a metabolic balance. Differences in metabolic parameters 
between cynomolgus monkeys, pigs, and humans have been 
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observed.7,43 Monkeys are characterized by high circulating 
C peptide and insulin levels, and by low glucose levels. In 
contrast, pigs exhibit low C peptide and insulin levels and 
higher blood glucose levels. Although both species respond 
to glucose and food stimulation, differences in insulin output 
and glucose homeostasis have been noted.
The molecular differences in porcine and monkey 
C peptide and insulin are not substantial, but these differ-
ences may interfere in their kinetics and in vivo activity. 
Human and porcine insulins, however, have demonstrated 
equivalent therapeutic activity.7 Human insulin requirements 
are between those of pigs and monkeys. This may be of 
importance in respect to the eventual translation of pig islet 
transplantation into clinical practice, since human insulin 
demands are lower than those of monkeys.7
Considering the performance of pig islets in NHPs, 
whose metabolic demand is higher than that of a pig, and 
more importantly higher than that of a human, we might 
argue that a good metabolic outcome could be reached in 
humans with pig islets. Although the definition of metabolic 
target in human recipients of pig islet transplantation has 
not been codified yet, reduction in glycated hemoglobin 
(HbA
1c
) and/or exogenous insulin requirements, if not insulin 
independence, are reasonable goals. As studies progress, 
a consensus will be reached.
Clinical trials of pig islet 
xenotransplantation
Because the results of islet xenotransplantation in NHPs are 
improving steadily and pigs with multiple genetic modifica-
tions are becoming more readily available, increased thought 
is being given to initiate clinical trials. Indeed, clinical trials 
of encapsulated pig islets have already been undertaken, 
although, with one exception, these have not been well 
regulated, and the results have not been reported fully. The 
exception is a trial currently being undertaken in New Zea-
land with oversight by that country’s Ministry of Health.44 
Although the results of islet-graft performance have not been 
disclosed yet, preliminary data indicate that no transmission 
of either porcine endogenous retroviruses (PERVs) or other 
porcine microorganisms was detected, as also reported by 
Heneine et al following the first trial of clinical fetal islet-like 
cluster transplantation in immunosuppressed patients.45,46 It 
would appear from these various trials that there have been 
no untoward complications, even though no or few clear 
benefits to the patients have been reported.
For clinical trials of free (ie, nonencapsulated) islet 
transplantation to be carried out, however, there is greater 
risk of such complications as infections, because of the 
need for immunosuppressive therapy. This is particularly 
important in patients with T1D, who are often young and 
may  therefore require immunosuppressive therapy for 
many years. Nevertheless, in those patients undergoing islet 
allotransplantation, the number of serious complications has 
to date been relatively few.47
The International 
Xenotransplantation  
Association guidelines
In 2009, the International Xenotransplantation Association 
(IXA) set up a group to advise on clinical trials of pig islet 
xenotransplantation.48 This committee investigated 1) the 
ethical requirements and regulatory framework that would 
be required, 2) the nature and housing of source pigs, 3) the 
preparation of the pig islet product and its testing, 4) preclini-
cal efficacy and complication data that might be required to 
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Figure 1 (A) Blood glucose, porcine C peptide measurements, and insulin requirements in a cynomolgus monkey that remained insulin-independent and normoglycemic for 
more than 1 year after adult porcine islet xenotransplantation (using a pig transgenic for the human complement-regulatory protein CD46) at the University of Pittsburgh. 
(B) Histopathology with insulin immunostaining of the liver 12 months after porcine islet xenotransplantation into the portal vein in the same cynomolgus monkey as in (A). 
islet morphology is well preserved. No islets were detectable in the monkey’s native pancreas.
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justify a clinical trial, 5) strategies to prevent transmission 
of PERVs, 6) patient selection, and 7) the matter of informed 
consent. The committee indicated that in the light of increas-
ing experience, the guidelines it had put forward might well 
require modification. There are certainly some areas where 
modification might be beneficial.
what, if any, experimental work  
needs to have been carried out  
before initiating a clinical trial?
The IXA committee recommended that no clinical trial should 
be undertaken unless there had been preclinical studies in 
NHPs. While it is true that these experiments are expensive 
and time-consuming, and may not always accurately reflect 
the outcome of islet xenotransplantation in humans, they can 
be an important step in assuring the safety of the patient. In 
that regard, by ensuring the safety of human patients, even 
if the NHP study fails, the cost cannot be considered too 
high. A case can be made that if there are good data from 
pig-to-rodent models to indicate that a clinical trial would 
provide a realistic possibility of benefit to the patient and 
would be safe, studies in NHPs may not be essential. Where 
encapsulated islets are concerned, the lack of the need for 
immunosuppressive therapy requires less stringent regulation, 
and evidence of efficacy from rodent models may possibly 
suffice under certain circumstances. However, when free 
islets are being transplanted, then some evidence of efficacy 
in a pig-to-NHP model will probably be expected by the 
national regulatory authorities.
what, if any, preliminary clinical  
studies need to have been carried  
out before initiating a clinical trial?
If the group planning a clinical trial has experience in the 
management of immunosuppressed patients with organ or 
islet allotransplants, then the need for studies in NHPs is 
perhaps reduced further. Centers with experience with islet 
isolation, particularly if it is of both human and pig islets, 
are also in a stronger position to initiate a clinical trial. 
 Experience in isolating islets (human or pig) under the con-
ditions required in a Good Manufacturing Practice facility 
would be considered essential.
what microbiological “safety” tests  
are required of the pigs and islets?
In the US, the approach from the Food and Drug Administration 
has been that the source pigs should be housed in a  biosecure 
facility and should be tested at intervals to ensure that 
any “product”, eg, islets, from the pig that is transplanted 
into human subjects is free of signif icant infectious 
microorganisms.49 An argument could be made that if the 
islets themselves are proven to be sterile, then this may be suf-
ficient to enable clinical islet transplantation to be undertaken. 
Most microorganisms could be excluded by testing the islets 
during the period of ex vivo culture before transplantation, 
but it may be difficult to demonstrate that the islets are free 
of significant viruses at this stage. Therefore, some testing 
of the herd to ensure that it is free of important viruses will 
probably be necessary.
The presence of PERVs in every pig cell nucleus has been 
of concern in the past,50 as the PERVs will undoubtedly be 
transferred to the patient with the islets. However, the data 
accumulated to date from humans and NHPs that have been 
exposed to pig tissues indicates that  transmission is extremely 
rare, and not associated with significant  complication. 
 Furthermore, methods are available today to minimize the 
risk of PERV activation.51
which patients should be selected  
for the initial clinical trial?
At present, most patients selected for islet allotransplantation 
are those experiencing significant life-threatening hypogly-
cemic episodes, and these would also be potential patients 
for pig islet xenotransplantation. The possibility of infections 
from unknown pathogens associated with the immunosup-
pression required for pig islet xenotransplantation needs to be 
weighed against the risk of developing major complications 
from diabetes at an early age.
On what basis would the trial  
be considered successful?
We would suggest that control of diabetes, or at least greatly 
reduced need for insulin therapy and a reduction in HbA
1c
, 
possibly with additional benefits (eg, a reduction in the 
number of hypoglycemic episodes) for .1 year, should be 
considered a successful trial. A reduction in HbA
1c
 levels, 
even while maintaining the same insulin requirements, 
would be beneficial to prevent the long-term complications 
of diabetes. It should be borne in mind that in the 1960s and 
1970s the function of kidney allotransplants was often only 
for some weeks or months, whereas today, with much greater 
experience and improved immunosuppressive agents, graft 
function frequently extends for very many years. Similarly, 
the results of islet allotransplantation, which were initially 
disappointing, have improved significantly during the past 
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14 years since the first encouraging report was published 
in 2000.52,53 Therefore, in the initial clinical trial of islet 
xenotransplantation, the expectation bar should not be set 
too high.
Regulation of the clinical trial
Oversight and regulation of clinical trials is clearly important, 
and any clinical trial of pig islet transplantation should be 
overseen by a local committee of experts who have the power 
and authority to discontinue the trial if necessary. Ideally, 
there should also be a national or international committee 
of experts to provide additional regulatory authority and 
organization.
Having emphasized that point, we would suggest that 
advancing the field of pig islet xenotransplantation, which 
has the potential of curing hundreds of thousands of patients 
with T1D, should be given very high priority, and regulations 
should not be so restrictive that they prohibit progress.55
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